[CLSTR]
< Back to situation

[REVISION HISTORY]

South Korean biotech government R&D funding

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-08-25 02:37 UTC → 2026-09-04 01:07 UTC · added removed

South Korean biotechnology and life science companies have secured continue to secure significant government R&D funding through various national initiatives. CHA Biotech was Pulse in Myers has been selected for the 2026 K-HERO Fostering ‘2026 Pharmaceutical and Support Project, managed by the Korea Industrial Bio-Venture Collaborative Technology Association. The Development Project’. In collaboration with Huons, the company will receive 3.15 billion KRW over 3.5 years to develop a next-generation cell and gene therapy platform, specifically focusing on the therapeutic candidate CHAGE-201 for idiopathic pulmonary fibrosis. Additionally, through programs hosted by the Ministry of SMEs and Startups, Pulse in Myers secured 3 billion KRW to accelerate the development and commercialization of ‘Pearl-101’, a subcutaneous formulation for refractory solid tumors. tumors, with the goal of completing Phase 1 clinical trial IND submissions. J&P Medi, an AI-based life science R&D platform company, was selected for the ‘Global TIPS’ program, securing has secured 6.2 billion KRW through 2030 to develop via the ‘Global TIPS’ program. The funding will support the development of an ‘AI-based Clinical OS’ for designed to automate the clinical trial automation. lifecycle by integrating data, documentation, and regulatory information. Under the Ministry of Science and ICT’s Bio and Medical Technology Development Program, CHA Biotech has been named a joint research institution for the ‘K-CGTAP’ project. This initiative, running from 2026 to 2030 with a total budget of approximately 13.7 billion KRW, aims to establish a Korea Cell and Gene Therapy Analysis Platform to meet global regulatory standards. Additionally, POSTECH has been selected to lead two major projects in Gyeongsangbuk-do, totaling 36 billion KRW over five years. These projects focus on developing next-generation plant exosome technology for bio-materials and original 3D bioprinting technologies for manufacturing regenerative therapies, such as patient-customized organ treatments and AI-driven cardiac muscle therapy.

Versions

  1. 2026-09-04 01:07 UTC South Korean biotech government R&D funding
  2. 2026-08-25 02:37 UTC South Korean biotech government R&D funding

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.